Brainstorm Cell Therapeutics (STU:GHDN) Total Liabilities : €8.19 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Brainstorm Cell Therapeutics Total Liabilities?

Brainstorm Cell Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was €8.19 Mil.

Brainstorm Cell Therapeutics's quarterly Total Liabilities increased from Sep. 2023 (€7.74 Mil) to Dec. 2023 (€8.31 Mil) but then declined from Dec. 2023 (€8.31 Mil) to Mar. 2024 (€8.19 Mil).

Brainstorm Cell Therapeutics's annual Total Liabilities increased from Dec. 2021 (€8.79 Mil) to Dec. 2022 (€10.82 Mil) but then declined from Dec. 2022 (€10.82 Mil) to Dec. 2023 (€8.31 Mil).

Brainstorm Cell Therapeutics Total Liabilities Historical Data

The historical data trend for Brainstorm Cell Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brainstorm Cell Therapeutics Total Liabilities Chart

Brainstorm Cell Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

16.88

12.98

8.79

10.82

8.31

Brainstorm Cell Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															11.87	8.89	7.74	8.31	8.19

Brainstorm Cell Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Brainstorm Cell Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	7.153	+	(0.616	+	0.545
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	8.31

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	3.859	-	-4.455
	=	8.31

Brainstorm Cell Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	6.285	+	(0.49	+	1.411
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	8.19

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	3.08	-	-5.106
	=	8.19

Brainstorm Cell Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Brainstorm Cell Therapeutics (STU:GHDN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brainstorm Cell Therapeutics Inc (STU:GHDN) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BCLI:USA GHDN:Germany

Address

1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019

Website

https://www.brainstorm-cell.com

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Brainstorm Cell Therapeutics (STU:GHDN) Headlines

No Headlines